Xortx announces share consolidation

Calgary, alberta, nov. 08, 2023 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that the company's board of directors has approved consolidating (the “consolidation”) its common shares (“shares”) on the basis of one post-consolidation share for every nine pre-consolidation shares, effective november 9, 2023 (the “effective date”).
XRTX Ratings Summary
XRTX Quant Ranking